These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38642596)

  • 1. Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC/ERS 2022 guidelines.
    D'Alto M; Badagliacca R; Airò E; Ameri P; Argiento P; Garascia A; Lombardi CM; Mulè M; Raineri C; Scelsi L; Vizza CD; Ghio S
    Vascul Pharmacol; 2024 Jun; 155():107374. PubMed ID: 38642596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary arterial hypertension in the elderly: Clinical perspectives.
    Rothbard N; Agrawal A; Fischer C; Talwar A; Sahni S
    Cardiol J; 2020; 27(2):184-193. PubMed ID: 30155860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New risk model by right ventricle - pulmonary arterial coupling and inferior vena cava from echocardiography in patients with conventional low-intermediate risk pulmonary artery hypertension under targeted treatment.
    Yang L; Luo D; Huang T; Li X; Zhang C; Fei H
    Echocardiography; 2024 Jun; 41(6):e15850. PubMed ID: 38818775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management.
    Correale M; Tricarico L; Grazioli D; Formica ES; Petrucci R; Persichella P; Di Biase M; Brunetti ND
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):725-738. PubMed ID: 31811420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of pulmonary arterial hypertension in Korea.
    Jang AY; Chung WJ
    Korean J Intern Med; 2019 Jul; 34(4):696-707. PubMed ID: 31272141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.
    Narechania S; Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):131-141. PubMed ID: 31594400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.
    Ahmed A; Ahmed S; Kempe D; Rådegran G
    Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of three-dimensional echocardiography in risk stratification in pulmonary arterial hypertension: a cross-sectional study.
    Liu BY; Wu WC; Zeng QX; Liu ZH; Niu LL; Tian Y; Luo Q; Zhao ZH; Quan RL; Lin JR; Wang H; He JG; Xiong CM
    Int J Cardiovasc Imaging; 2020 Apr; 36(4):577-584. PubMed ID: 31853819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension.
    Wright L; Dwyer N; Wahi S; Marwick TH
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 1):2103-2111. PubMed ID: 30343091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and risk factors for pulmonary arterial hypertension associated with primary Sjögren's syndrome: 15 new cases from a single center.
    Zhang N; Zhao Y; Wang H; Sun W; Chen M; Fan Q; Yang Z; Wei W
    Int J Rheum Dis; 2019 Sep; 22(9):1775-1781. PubMed ID: 31368254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
    Chida-Nagai A; Sagawa K; Tsujioka T; Fujimoto T; Taniguchi K; Sasaki O; Izumi G; Yamazawa H; Masaki N; Manabe A; Takeda A
    Heart Vessels; 2020 Sep; 35(9):1307-1315. PubMed ID: 32285188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study.
    Diez M; Cáneva J; Diez A; Perna ER; Aimone D; Bosio M; Márquez LL; Brasca DG; Vulcano N; Daghero F; Burgos LM; Favaloro L; Escalante JP; Coronel ML; Fernández A; Chávez Á; Secco L;
    Respir Med Res; 2023 Jun; 83():100945. PubMed ID: 36563553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
    Distler O; Bonderman D; Coghlan JG; Denton CP; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Vonk MC; Di Scala L; Lemarie JC; Perchenet L; Hachulla É
    Arthritis Rheumatol; 2024 May; 76(5):777-782. PubMed ID: 38146100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines.
    Li Y; Qian J; Dong X; Zhao J; Wang Q; Wang Y; Zeng X; Tian Z; Li M
    Arthritis Res Ther; 2024 May; 26(1):109. PubMed ID: 38802957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
    Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
    Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right Ventricle-Specific Three-Dimensional Wall Motion Tracking for Visualization of Regional Wall Motion Abnormality in Patients With Pulmonary Arterial Hypertension.
    Moriyama H; Murata M; Kataoka M; Kawakami T; Endo J; Kohno T; Itabashi Y; Seo Y; Iwao Y; Fukuda K
    Circ Cardiovasc Imaging; 2019 Apr; 12(4):e008795. PubMed ID: 30939920
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.
    Coons JC; Pogue K; Kolodziej AR; Hirsch GA; George MP
    Curr Cardiol Rep; 2019 Nov; 21(11):141. PubMed ID: 31758342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.